Literature DB >> 1167821

Deoxycorticosterone excretion in normal, hypertensive and hypokalaemic subjects.

C L Cope, S Loizou.   

Abstract

1. Radioimmunoassay has been used to detect and estimate the urinary excretion of deoxycorticosterone (DOC) in normal, hypertensive and hypokalaemic subjects. The range of excretions in ten healthy normal subjects was 41-232 pmol (13.7-76.7 ng) daily, with a mean of 124 pmol (41 ng). 2. In fourteen subjects with essential hypertension without metabolic disturbance the range found was 29-144 pmol (9.7-47.7 ng) daily, with a mean of 87 pmol (28.8 ng), which is not significantly different from that in normal subjects. 3. In twelve patients with Cushing's syndrome due to adrenal cortical hyperplasia the range found was 26-542 pmol (8.7-179 ng). Ten of these twelve patients had values within normal limits. 4. Of nine subjects showing hypokalaemia, eight had elevated excretion of deoxycorticosterone with values from 263 to 5515 pmol (87-1820 ng) daily. Seven of these were hypertensive and two were normotensive. The elevated excretion of deoxycorticosterone found in hypokalaemic subjects is thus not confined to those with hypertension. 5. No correlation has been found between excretion rates for aldosterone and deoxycorticosterone. Raised excretion of the latter provides an indicator of disturbed adrenal cortical metabolism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1167821     DOI: 10.1042/cs0480097

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  8 in total

1.  Methodological aspects for free hormone estimation using microencapsulated antibody method--the effects of hormone binding protein on permeability of microcapsule membrane.

Authors:  T Hashimoto; K Ishibashi; F Matsubara
Journal:  Ann Nucl Med       Date:  1990-03       Impact factor: 2.668

2.  Medical science and technology at the Royal Postgraduate Medical School: the first 50 years.

Authors:  C C Booth
Journal:  Br Med J (Clin Res Ed)       Date:  1985 Dec 21-28

3.  Rapid reduction of blood pressure with acute oral labetalol.

Authors:  A B Davies; V Bala Subramanian; B Gould; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

4.  Effect of acute hyperglycaemia on plasma potassium and aldosterone levels in type 2 (non-insulin-dependent) diabetes.

Authors:  J Rosenstock; S A Loizou; I E Brajkovich; K Mashiter; G F Joplin
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

5.  Effect of metoprolol on 24-hour urinary excretion of adrenal steroids and kallikrein in patients with essential hypertension.

Authors:  E Fritschka; R Gotzen; R Kittler; M Schöneshöfer
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

6.  Adrenogenital syndrome due to 11-beta-hydroxylase deficiency with skeletal abnormalities and pulmonary stenosis.

Authors:  K Ajlouni; M El-Zaheri; M Habbab; Y Qoussous; M El-Khateeb
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

7.  Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.

Authors:  N O Lunell; P Hjemdahl; B B Fredholm; H Nisell; B Persson; J Wager
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

8.  Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency with skeletal abnormalities.

Authors:  K M Ajlouni; M A Arnaout; Y Qoussous
Journal:  J Endocrinol Invest       Date:  1996-05       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.